Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Mehta, Nehal N. [2 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, M. Alan [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15960
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [41] Long-term safety of tildrakizumab in patients with psoriasis: incidence of malignancies through 3 years from 2 phase 3 trials
    Reich, K.
    Griffiths, C. E.
    Iversen, L.
    Peserico, A.
    Pau-Charles, I.
    Blauvelt, A.
    Thaci, D.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 103 - 103
  • [42] The application of Dermatology Life Quality Index-Relevant (DLQI-R) in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: post hoc analysis from the reSURFACE 2 phase III trial
    Laws, P.
    Gaarn Du Jardin, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E41 - E42
  • [43] Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
    Ritchlin, Christopher T.
    Giles, Jon T.
    Ogdie, Alexis
    Gomez-Reino, Juan J.
    Helliwell, Philip
    Young, Pamela
    Wang, Cunshan
    Wu, Joseph
    Romero, Ana Belen
    Woolcott, John
    Stockert, Lori
    ACR OPEN RHEUMATOLOGY, 2020, 2 (10) : 543 - 554
  • [44] Long-term safety of tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis through 148 weeks from two phase 3 trials
    Reich, K.
    Thaci, D.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Lebwohl, M.
    Cantrell, W.
    Rozzo, S.
    Blauvelt, A.
    Iversen, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 47 - 48
  • [45] Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
    Warren, R. B.
    Carrascosa, J. M.
    Fumero, E.
    Schoenenberger, A.
    Lebwohl, M. G.
    Szepietowski, J. C.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : 919 - 927
  • [46] TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND METABOLIC SYNDROME: A POST-HOC ANALYSIS OF PHASE 3 STUDIES
    Ritchlin, C.
    Giles, J.
    Ogdie, A.
    Gomez-Reino, J.
    Stockert, L.
    Young, P.
    Wang, C.
    Romero, A. B.
    Kudlacz, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1023 - 1023
  • [47] Effect of lurasidone or risperidone on metabolic syndrome status in patients with schizophrenia: a post hoc analysis of a long-term study
    Newcomer, J.
    Pikalov, A.
    Watabe, K.
    Cucchiaro, J.
    Rajagopalan, K.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S558 - S559
  • [48] Application of the statistical method to convert published PASI 50/75/90/100 into absolute PASI response rate in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab based on data from two pivotal phase 3 studies (reSURFACE 1/2)
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
  • [49] Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years
    Chopra, Arvind
    Shobha, Vineeta
    Chandrashekara, Srikantiah
    Veeravalli, Sarath C. M.
    Sharma, Reena
    Rao, Uppuluri R.
    Pandya, Sapan
    Wagh, Shrikant
    Kadel, Jugal K.
    Thorat, Amit, V
    Adhav, Charles
    Estrella, Paul Santos
    Yu, Wei
    Kwok, Kenneth
    Wouters, Ann
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (07) : 882 - 897
  • [50] SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
    Jones, H. N.
    Strand, V.
    Schulze-Koops, H.
    Mysler, E.
    Kinch, C.
    Gruben, D. C.
    Germino, R.
    Connell, C. A.
    Eder, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 565 - 566
12345